The prevalence of PBRM1 mutation (NSCLC: 84/2767, 3.04%; ccRCC: 162/402, 40.30% in The Cancer Genome Atlas (TCGA)) and the proportion of truncating mutation (NSCLC: 51/84, 60.17%; ccRCC: 144/162, 93.51% in TCGA) were relatively low in NSCLC (Supplementary Fig. 2). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.